Cargando…

Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes

Previous studies show that children who later progress to type 1 diabetes (T1D) have decreased preautoimmune concentrations of multiple phospholipids as compared with nonprogressors. It is still unclear whether these changes associate with development of β-cell autoimmunity or specifically with clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Orešič, Matej, Gopalacharyulu, Peddinti, Mykkänen, Juha, Lietzen, Niina, Mäkinen, Marjaana, Nygren, Heli, Simell, Satu, Simell, Ville, Hyöty, Heikki, Veijola, Riitta, Ilonen, Jorma, Sysi-Aho, Marko, Knip, Mikael, Hyötyläinen, Tuulia, Simell, Olli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749353/
https://www.ncbi.nlm.nih.gov/pubmed/23630305
http://dx.doi.org/10.2337/db13-0159
_version_ 1782281186393980928
author Orešič, Matej
Gopalacharyulu, Peddinti
Mykkänen, Juha
Lietzen, Niina
Mäkinen, Marjaana
Nygren, Heli
Simell, Satu
Simell, Ville
Hyöty, Heikki
Veijola, Riitta
Ilonen, Jorma
Sysi-Aho, Marko
Knip, Mikael
Hyötyläinen, Tuulia
Simell, Olli
author_facet Orešič, Matej
Gopalacharyulu, Peddinti
Mykkänen, Juha
Lietzen, Niina
Mäkinen, Marjaana
Nygren, Heli
Simell, Satu
Simell, Ville
Hyöty, Heikki
Veijola, Riitta
Ilonen, Jorma
Sysi-Aho, Marko
Knip, Mikael
Hyötyläinen, Tuulia
Simell, Olli
author_sort Orešič, Matej
collection PubMed
description Previous studies show that children who later progress to type 1 diabetes (T1D) have decreased preautoimmune concentrations of multiple phospholipids as compared with nonprogressors. It is still unclear whether these changes associate with development of β-cell autoimmunity or specifically with clinical T1D. Here, we studied umbilical cord serum lipidome in infants who later developed T1D (N = 33); infants who developed three or four (N = 31) islet autoantibodies, two (N = 31) islet autoantibodies, or one (N = 48) islet autoantibody during the follow-up; and controls (N = 143) matched for sex, HLA-DQB1 genotype, city of birth, and period of birth. The analyses of serum molecular lipids were performed using the established lipidomics platform based on ultra-performance liquid chromatography coupled to mass spectrometry. We found that T1D progressors are characterized by a distinct cord blood lipidomic profile that includes reduced major choline-containing phospholipids, including sphingomyelins and phosphatidylcholines. A molecular signature was developed comprising seven lipids that predicted high risk for progression to T1D with an odds ratio of 5.94 (95% CI, 1.07–17.50). Reduction in choline-containing phospholipids in cord blood therefore is specifically associated with progression to T1D but not with development of β-cell autoimmunity in general.
format Online
Article
Text
id pubmed-3749353
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-37493532014-09-01 Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes Orešič, Matej Gopalacharyulu, Peddinti Mykkänen, Juha Lietzen, Niina Mäkinen, Marjaana Nygren, Heli Simell, Satu Simell, Ville Hyöty, Heikki Veijola, Riitta Ilonen, Jorma Sysi-Aho, Marko Knip, Mikael Hyötyläinen, Tuulia Simell, Olli Diabetes Original Research Previous studies show that children who later progress to type 1 diabetes (T1D) have decreased preautoimmune concentrations of multiple phospholipids as compared with nonprogressors. It is still unclear whether these changes associate with development of β-cell autoimmunity or specifically with clinical T1D. Here, we studied umbilical cord serum lipidome in infants who later developed T1D (N = 33); infants who developed three or four (N = 31) islet autoantibodies, two (N = 31) islet autoantibodies, or one (N = 48) islet autoantibody during the follow-up; and controls (N = 143) matched for sex, HLA-DQB1 genotype, city of birth, and period of birth. The analyses of serum molecular lipids were performed using the established lipidomics platform based on ultra-performance liquid chromatography coupled to mass spectrometry. We found that T1D progressors are characterized by a distinct cord blood lipidomic profile that includes reduced major choline-containing phospholipids, including sphingomyelins and phosphatidylcholines. A molecular signature was developed comprising seven lipids that predicted high risk for progression to T1D with an odds ratio of 5.94 (95% CI, 1.07–17.50). Reduction in choline-containing phospholipids in cord blood therefore is specifically associated with progression to T1D but not with development of β-cell autoimmunity in general. American Diabetes Association 2013-09 2013-08-15 /pmc/articles/PMC3749353/ /pubmed/23630305 http://dx.doi.org/10.2337/db13-0159 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Orešič, Matej
Gopalacharyulu, Peddinti
Mykkänen, Juha
Lietzen, Niina
Mäkinen, Marjaana
Nygren, Heli
Simell, Satu
Simell, Ville
Hyöty, Heikki
Veijola, Riitta
Ilonen, Jorma
Sysi-Aho, Marko
Knip, Mikael
Hyötyläinen, Tuulia
Simell, Olli
Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title_full Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title_fullStr Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title_full_unstemmed Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title_short Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes
title_sort cord serum lipidome in prediction of islet autoimmunity and type 1 diabetes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749353/
https://www.ncbi.nlm.nih.gov/pubmed/23630305
http://dx.doi.org/10.2337/db13-0159
work_keys_str_mv AT oresicmatej cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT gopalacharyulupeddinti cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT mykkanenjuha cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT lietzenniina cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT makinenmarjaana cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT nygrenheli cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT simellsatu cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT simellville cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT hyotyheikki cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT veijolariitta cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT ilonenjorma cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT sysiahomarko cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT knipmikael cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT hyotylainentuulia cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes
AT simellolli cordserumlipidomeinpredictionofisletautoimmunityandtype1diabetes